Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients

Clinical and Molecular Hepatology

Jeong Han Kim¹  Soon Young Ko¹  Won Hyeok Choe¹  So Young Kwon¹  Chang Hong Lee¹ 

[1] Digestive Disease Center, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.;

关键词: Chronic hepatitis B;    Lamivudine;    Adefovir;    Resistance;    Hepatocellular carcinoma;   

DOI  :  10.3350/cmh.2013.19.3.273

来源: DOAJ

【 摘 要 】

Background/AimsLamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients.MethodsThe medical records of CHB patients who developed LAM resistance and were treated with LAM plus ADV combination therapy for more than 6 months were reviewed. Their virological response (VR; undetectable HBV DNA) and biochemical response (BR; alanine aminotransferase normalization) were evaluated, and the findings of HCC and non-HCC patients were compared.ResultsThe data from 104 patients (19 with HCC and 85 without HCC) were analyzed. The VR rates did not differ significantly between the HCC and non-HCC groups: 33.3% vs. 55.6% at 12 months (P=0.119), 58.3% vs. 67.2% at 24 months (P=0.742), 50% vs. 69.8% at 36 months (P=0.280), and 66.7% vs. 71.0% at 48 months (P=1.000). The BR rates also did not differ significantly between the groups: 55.6% vs. 84.0% at 12 months (P=0.021), 58.3% vs. 83.8% at 24 months (P=0.057), 70.0% vs. 77.8% at 36 months (P=0.687), and 66.7% vs. 80.6% at 48 months (P=0.591).ConclusionsThe efficacy of LAM plus ADV combination therapy is comparable in HCC and non-HCC patients.

【 授权许可】

Unknown